SCHEMBL17859664

SCHEMBL17859664

CCc1ccc(C(=O)Oc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
RORC P51449 1/20 0.45
PLK1 P53350 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
GAA P10253 4/20 0.41
POLB P06746 2/20 0.41
LMNA P02545 2/20 0.41
AGTR1 P30556 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 4/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
MAPK1 P28482 1/20 0.40
NLRP1 Q9C000 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5706248 0.83 HPGD (0.53) ALDH1A1PLK1KMT2ALMNANPC1
SCHEMBL9161406 0.80 LMNA (0.50) ALDH1A1KMT2ATDP1GAALMNA
SCHEMBL19220417 0.76 PRSS1 (0.52) ALDH1A1PLK1LOXL2KMT2ATDP1
SCHEMBL13560668 0.75 ALDH1A1 (0.53) ALDH1A1PLK1LOXL2TDP1POLB
SCHEMBL12154260 0.75 ALDH1A1 (0.48) ALDH1A1PLK1LOXL2KMT2ATDP1
SCHEMBL6939316 0.75 KMT2A (0.56) ALDH1A1KMT2AGAAPOLBLMNA
SCHEMBL12154259 0.75 ALDH1A1 (0.48) ALDH1A1PLK1LOXL2KMT2ATDP1
SCHEMBL11527289 0.75 KMT2A (0.60) ALDH1A1KMT2AGAAPOLBLMNA
SCHEMBL12154217 0.74 ALDH1A1 (0.57) ALDH1A1PLK1KMT2ALMNAMAPT
SCHEMBL12154283 0.74 ALDH1A1 (0.57) ALDH1A1PLK1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2020-06-18 US disclosed
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG (CH) 2020-06-09 US disclosed
US-20180002368-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2018-01-04 US disclosed
WO-2016098028-A1 END CAPPED NUCLEIC ACID MOLECULES NOVARTIS AG (CH) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 ALDH1A1 3871/4885RORC 2849/4885PLK1 1757/4885
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 ALDH1A1 3871/4885RORC 2849/4885PLK1 1757/4885
US-20180002368-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NSUN2, NSUN3, RNGTT ALDH1A1 4255/4885RORC 2924/4885PLK1 2126/4885
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA RNGTT, NSUN3, NSUN2 ALDH1A1 3685/4885RORC 2788/4885PLK1 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.